Akebia Ther Stock Investor Sentiment
AKBA Stock | USD 2.21 0.05 2.21% |
About 55% of Akebia Ther's investor base is interested to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are impartial. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
Akebia |
Akebia Ther Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Akebia Ther Maximum Pain Price Across April 17th 2025 Option Contracts
Akebia Ther's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Akebia Ther close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Akebia Ther's options.
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.
Akebia Ther Performance against Dow Jones
Price Growth (%) |
Timeline |
1 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/02/2025 |
2 | Disposition of 20100 shares by Frieson Ron of Akebia Ther at 0.45 subject to Rule 16b-3 | 01/17/2025 |
3 | Acquisition by Ostrowski Erik of 292300 shares of Akebia Ther at 2.24 subject to Rule 16b-3 | 01/31/2025 |
4 | Disposition of 55621 shares by Nicholas Grund of Akebia Ther at 2.1 subject to Rule 16b-3 | 02/03/2025 |
5 | Akebia Therapeutics, Inc. CEO John P. Butler Sells 144,250 Shares | 02/05/2025 |
6 | Akebia Therapeutics NASDAQAKBA investor five-year losses grow to 80 percent as the stock sheds US55m this past week | 02/26/2025 |
7 | Disposition of 7144 shares by Steven Burke of Akebia Ther at 1.83 subject to Rule 16b-3 | 03/03/2025 |
8 | Akebia Therapeutics to Report Fourth Quarter and Full Year 2024Financial Results and Discuss Recent Business Highlights | 03/06/2025 |
9 | Akebia Therapeutics Projected to Post Quarterly Earnings on Thursday | 03/12/2025 |
10 | Akebia GAAP EPS of -0.10 misses by 0.02, revenue of 46.49M beats by 9.13M | 03/13/2025 |
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |